Status:
COMPLETED
The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial
Lead Sponsor:
Yonsei University
Conditions:
Colon Cancer
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) has been reported to be an effective treatment approach for peritoneal cancer, however, the stress response to HIPEC is maj...
Eligibility Criteria
Inclusion
- patients between 20 and 70 years old
- obtaining written informed consent from the patients who were undergoing hyperthermic intraperitoneal chemotherapy (HIPEC) cytoreductive surgery
- weights under 90 kg and BMI under 32
Exclusion
- emergency operation
- re-operations
- combined surgery over 4 departments.
- cardiac disease (unstable angina, congestive heart failure, valvular heart disease)
- Ventricular conduction abnormality
- prior pacemaker insertion
- uncontrolled hypertension (diastolic blood pressure \> 110mmHg)
- bradycardia (HR \< 40 Bpm)
- cerebral vascular disease (cerebral hemorrhage, cerebral ischemia)
- hepatic or renal failure
- patients who take antiarrythmic agent
- neurological or psychiatric illnesses
- foreigner and patient who can not read the letter
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 27 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03370588
Start Date
December 1 2017
End Date
May 27 2019
Last Update
December 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine
Seoul, South Korea, 03722